FDA inspectors continue to roll through Dr. Reddy’s plants in India and continue to find issues along the way.

Japan’s Daiichi Sankyo has been in cost-cutting mode for several years, but says it will invest about $135 million in its manufacturing operations in Japan as…

The FDA, which banned APIs coming from a Divi’s plant in India, has followed that with a warning letter that savages the facility for a lack of data integrity.

For nearly two years Teva struggled with impurity issues for an API manufactured at a plant in China.

Sun Pharma has had another setback in its manufacturing for the U.S. market with the FDA laying out nearly a dozen observations for a solid dose formulation…

Swedish CDMO Recipharm’s growing global footprint in 2016 has positioned the company to take advantage of what is expected to be more consolidation and growth…

Fujifilm is investing about $130 million in its U.S. and U.K. plants to increase biologics manufacturing as it races to capture a piece of the growing business.

The FDA has nailed another Teva manufacturing facility with a warning letter, this time for an API facility in China.

Another Mylan plant in India has been issued a warning letter.